期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 83, 期 5, 页码 1239-1253出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2020.03.131
关键词
basal cell carcinoma; checkpoint inhibitor; CTLA-4 inhibitor; cutaneous lymphomas; cutaneous malignancies; cutaneous squamous cell carcinoma; immunotherapy; Kaposi sarcoma; melanoma; Merkel cell carcinoma; PD-1 inhibitor; PD-L1 inhibitor; skin cancer
类别
资金
- National Cancer Institute Cancer Center support grant [P30 CA008748]
- National Institute of Arthritis and Musculoskeletal and Skin Diseases [U01AR07751]
- National Cancer Institute [5P01CA225517]
As the incidence of cutaneous malignancies continues to rise and their treatment with immunotherapy expands, dermatologists and their patients are more likely to encounter immune checkpoint inhibitors. While the blockade of immune checkpoint target proteins (cytotoxic T-lymphocyte-associated protein-4, programmed cell death-1, and programmed cell death ligand-1) generates an antitumor response in a substantial fraction of patients, there is a critical need for reliable predictive biomarkers and approaches to address refractory disease. The first article of this Continuing Medical Education series reviews the indications, efficacy, safety profile, and evidence supporting checkpoint inhibition as therapeutics for metastatic melanoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma. Pivotal studies resulting in the approval of ipilimumab, pembrolizumab, nivolumab, cemiplimab, and avelumab by regulatory agencies for various cutaneous malignancies, as well as ongoing clinical research trials, are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据